These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1357739)

  • 1. Clinical aspects of gastroduodenal ulcer recurrence: an overview.
    Bynum TE
    Scand J Gastroenterol Suppl; 1992; 191():1-3. PubMed ID: 1357739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longer relapse-free period after sucralfate than after H2-blocker treatment of duodenal and gastric ulcers.
    Domschke S; Domschke W
    Am J Med; 1991 Aug; 91(2A):74S-83S. PubMed ID: 1679297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance therapy with sucralfate in duodenal ulcer: genuine prevention or accelerated healing of ulcer recurrence?
    Bynum TE; Koch GG
    Am J Med; 1991 Aug; 91(2A):84S-90S. PubMed ID: 1882909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of protective drugs in the prevention of ulcer relapse.
    Ota S; Terano A
    J Gastroenterol; 1994 Jul; 29 Suppl 7():139-40. PubMed ID: 7921147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of peptic ulcer disease with sucralfate: a review.
    Hunt RH
    Am J Med; 1991 Aug; 91(2A):102S-106S. PubMed ID: 1882894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of duodenal ulcer with sucralfate.
    Lam SK
    Scand J Gastroenterol Suppl; 1991; 185():22-8. PubMed ID: 1683491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug therapy for preventing peptic ulcer recurrence.
    Sutherland JE
    Am Fam Physician; 1986 Nov; 34(5):141-4. PubMed ID: 2877559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topically active drugs in the treatment of peptic ulcers. Focus on colloidal bismuth subcitrate and sucralfate.
    Bianchi Porro G; Parente F
    J Clin Gastroenterol; 1992 Apr; 14(3):192-8. PubMed ID: 1348753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical treatment of peptic ulcer disease.
    Rubin W
    Med Clin North Am; 1991 Jul; 75(4):981-98. PubMed ID: 1677060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of sucralfate-induced ulcer healing and relapse.
    Lam SK
    Am J Med; 1989 Jun; 86(6A):122-6. PubMed ID: 2660554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of peptic ulcers--acid reduction or cytoprotection?
    Glise H; Carling L; Hallerbäck B; Kagevi I; Solhaug JH; Svedberg LE; Wahlby L
    Scand J Gastroenterol Suppl; 1987; 140():39-47. PubMed ID: 3328284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sucralfate maintenance therapy in duodenal ulcer disease. A review.
    Bolin TD
    Am J Med; 1989 Jun; 86(6A):148-51. PubMed ID: 2567571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of maintenance therapy in peptic ulcer disease. The ACG Committee on FDA-Related Matters.
    Am J Gastroenterol; 1988 Jun; 83(6):607-17. PubMed ID: 2897783
    [No Abstract]   [Full Text] [Related]  

  • 14. Duodenal ulcer. Who should have long-term maintenance therapy?
    Zuckerman G
    Postgrad Med; 1987 Oct; 82(5):52-3, 57-8, 60. PubMed ID: 2890147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosa protectives: sucralfate and colloidal bismuth subcitrate in peptic ulcer disease.
    Tytgat GN; Nio CY
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():152-61. PubMed ID: 3660894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The other option in peptic ulcer therapy.
    Halter F
    S Afr Med J; 1984 Jun; 65(25):996-1000. PubMed ID: 6374932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of H2-receptor antagonist in the treatment of peptic ulcer disease in children.
    Tam PK; Saing H
    J Pediatr Gastroenterol Nutr; 1989 Jan; 8(1):41-6. PubMed ID: 2567346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sucralfate: worldwide experience in recurrence therapy.
    Marks IN
    J Clin Gastroenterol; 1987; 9 Suppl 1():18-22. PubMed ID: 3302008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The natural history of peptic ulcer disease: the influence of H2-antagonist treatment.
    Bianchi Porro G; Petrillo M
    Scand J Gastroenterol Suppl; 1986; 121():46-52. PubMed ID: 2876513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists.
    Tytgat GN; Lamers CB; Hameeteman W; Jansen JM; Wilson JA
    Aliment Pharmacol Ther; 1987 Feb; 1(1):31-8. PubMed ID: 2908747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.